Skip to content

Geron GERN Accrued Expenses

Accrued Expenses at other companies

Incyte logo
IncyteINCY
$124.92M+21.5%
Immunome logo
ImmunomeIMNM
$21.88M+23.9%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$74.84M+33.7%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$19M+11.8%
Celcuity logo
CelcuityCELC
$1.25M-94.5%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$3.24M+1.9%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's accrued expenses?
Geron (GERN) reported accrued expenses of $9.49M in Q1 2026.
How has Geron's accrued expenses changed year-over-year?
Geron's accrued expenses decreased by 1.2% year-over-year, from $9.6M to $9.49M.
What is the long-term trend for Geron's accrued expenses?
Over 5 years (2020 to 2025), Geron's accrued expenses has grown at a 30.0% compound annual growth rate (CAGR), from $8.22M to $30.5M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.